Investigational drug · Phase 2
ART0380
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Cancer, Metastatic Cancer, Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ART0380"
First trial start
2021
Jan 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ART0380", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Cancer
- Metastatic Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Endometrial Cancer
- Metastatic Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Acinar Cell Carcinoma
Approved drugs for the same conditions: Colorectal cancer · Ovarian cancer · Pancreatic cancer · Endometrial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ART0380" as an intervention, largest first.
Artios Pharma LtdIndustry
NCT04657068 · 542 participants (planned) · Start Jan 27, 2021 · Primary completion Jan 2028
Drug: ART0380; Gemcitabine and 1 more · For: Advanced Cancer; Metastatic Cancer; Ovarian Cancer and 6 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 88 sites in all
Artios Pharma LtdIndustry
NCT05798611 · 36 participants · Start Sep 6, 2023 · Primary completion Nov 15, 2024
Drug: ART0380 · For: Advanced Solid Tumor; Recurrent Endometrial Cancer; Metastatic Cancer
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors.
Qin S, An J, Qiao W, et al. · Biomed Pharmacother 2026
- Recent advances in small molecule ATR kinase inhibitors as anticancer agents.
Singh G, Sharma R, Gautam V, et al. · Future Med Chem 2026
- Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature.
Kciuk M, Wanke K, Marciniak B, et al. · Int J Mol Sci 2026
- Ruthenium-Catalyzed Enantioselective Alkylation of Sulfenamides: A General Approach for the Synthesis of Drug Relevant S-Methyl and S-Cyclopropyl Sulfoximines.
Boyer ZW, Kwon NY, Ellman JA · J Am Chem Soc 2025
- Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers.
Carroll CL, Johnson MG, Ding Y, et al. · J Med Chem 2024
- Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.
Pilié PG, Giuliani V, Wang WL, et al. · Clin Cancer Res 2024
Also in development for Advanced Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- ALK201Phase 22 trials
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- Personalized Neoantigen Peptide VaccinePhase 22 trials
Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer
- TST001Phase 22 trials
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.